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Abstract 
 
The R&D process in the pharmaceutical industry has a long and dynamic life then it is an ideal field of 
application for ROA. Actually, ROA implementation, as widely demonstrated in literature, is narrowed to 
very limited cases because its perceived complexity.  
This research wants to suggest a simplified method, respect the ones available in literature, that could 
foster the use of ROA: we built up an integer linear programming model, based on a model available in 
literature, useful for selecting a balanced R&D portfolio from a set of candidate drugs. The model has been 
tested through a case study.  
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1. Introduction 
 
Drugs have great social relevance, since their use has a considerable influence on people’s quality of life, 
wellness, diseases progress and recovery chances. For these reasons, pharmaceutical companies have 
always focused their attention on innovation, in order to find a cure to the illnesses which still do not have 
satisfactory treatments and to improve already existing drugs. However, there are other reasons pushing 
pharmaceutical firms into making large efforts on Research and Development (R&D). In fact, developing a 
new drug allows pharmaceutical companies to ask regulatory agencies, like FDA (Food & Drugs 
Administration) in the US, for a patent which protects the innovative drug incomes, preventing other 
companies from using the same chemical structure. Therefore, pharmaceutical firms struggle to discover 
and develop promising compounds before competitors do. This allows them to beat competitors in the 
winner-takes-all patent race and, once the drug is introduced in the market, to gain great revenues useful 
also to fund other R&D projects. This is particularly true if the drug eventually becomes a blockbuster, 
namely a successfully drug whose annual revenues exceeds one billion dollars. 
Thus, due to its focus on innovation, R&D process is extremely important in pharmaceutical industry, as it 
allows a company to achieve high profits and growth rates. This importance is witnessed by the financial 
effort that pharmaceutical firms carried out during the last decades to fund R&D activities. In the US, the 
R&D intensity, which is the ratio between expenditures for R&D and firm revenue, rose from 12% in the 
1970 to over 20% in the late 1990’s and it’s now approximately steady around the value of 19% (see Fig. 1) 
[1]. 
 
2 
 
 
Fig. 1. R&D as a percent of US sales for pharmaceutical companies (1970-2009) (source: PhRMA) 
 
In 2009, pharmaceutical companies invested US$ 65,3 billion in R&D, 37% more than 5 years before [2].  
Since the above mentioned importance of R&D for pharmaceutical companies, it’s vital to evaluate R&D 
projects in the most proper and accurate way in order to decide whether to invest in them or not.  
Moreover there are fewer and fewer new molecular entities that are ready to be brought to the market per 
USD invested in R&D, so the importance of a promising portfolio selection assumes a growing importance. 
Traditional evaluation methods, based on discounted cash flow such as net present value, are not able to 
catch the actual value created by this kind of projects because of their inability to take account of the 
flexibility owned by managers, who might interrupt the drug development process and consequently 
abandon the project if it became no longer favourable. Therefore, these models could underrate some 
projects, especially those that are riskier and set in a dynamic environment, eventually leading to reject 
some profitable opportunities. Thus, alternative tools, able to adapt to the features of pharmaceutical R&D 
projects, are required, in order to correctly assess their value. This article deals with real options based 
methods used to evaluate pharmaceutical R&D projects. Indeed, they allow to take account of uncertainty 
and flexibility inherent in the pharmaceutical R&D process and to reckon with the value of future chances 
deriving from the acquisition of knowledge during the drug development process. As a result, real options 
methods are able to quantify this added value in a more accurate way than the traditional ones. 
Section 2 describes the R&D process of a new drug, pointing out the risks inherent in it, while Section 3 
shows the methods to evaluate pharmaceutical R&D projects, comparing the traditional ones with those 
based on real options and presenting the most used applications of them. Literature review is reported in 
Section 4. The proposed model is introduced in section 5: it is a mixed-integer linear programming model 
useful for selecting a balanced optimal product portfolio from a set of candidate drugs at different stages in 
their R&D process. This model results from the adjustment of a pre-existing model to which some 
simplifications, useful for favouring its spread among the companies, and some modifications, useful for 
achieving balance in the portfolio selection, have been introduced. As a result, this model is quiet easy to 
implement in a spreadsheet for computing its solution, as shown in Section 6, where it is applied to solve 
an actual pharmaceutical portfolio selection case study. In the same section, a sensitivity analysis is also 
shown, which was carried out to study the variation of portfolio value and composition caused by changes 
in budget limitations of a company. Finally, in section 7 some conclusions are drawn and some suggestions 
for possible further studies are proposed. 
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 2. Pharmaceutical R&D: new drug development
 
According to recent analysis [3], only one of 10
pharmaceutical companies makes it through its R&D process and is approved for patient use by the FDA. 
Potential new drugs pass through several stages on their way from research laboratories to pharmacy 
shelves. These phases are well defined and strongly regulated by regulatory agencies as the above 
mentioned FDA. That’s why the pharmaceutical R&D process, 
years, can be fairly modelled as shown in figure 2.
 
 
The development of a new drug starts with a complex and highly expensive research of potential 
candidates compounds, in which m
of them able to affect the under analysis disease. About 250 of the starting molecules enter the following 
phase, called pre-clinical phase, during which the survived compounds are tested 
order to investigate the presence of possible side effects. If this happens and risk
the R&D process of the drug will be interrupted. Conversely, a company may ask regulatory agencies such 
as FDA for approval, in order to begin the subsequent phase named 
carried out on human beings. On average, out of the 250 chemical compounds that entered the pre
phase, only 5 are able to continue to the following one. Clinic
the first one, phase I, 20-30 healthy volunteers, treated with different doses of the examining drug, are 
used to determine safety and dosage of the medicine. In the next one, 
100-300 patient volunteers who are plagued by the targeted sickness, in order to look for efficacy and side 
effects. This is usually done by comparing the effect of the molecule on the volunteers with the one stem 
from the use of a placebo. Finally, 
information about the experiment, are used to test the effectiveness of the new drug, in order to 
demonstrate that it works better than the already existing treatments. If clinical tes
completed, a company will send the FDA an approval request for a New Drug Application (NDA), submitting 
all the data obtained during the clinical testing. On average, only one of the five chemical compounds
which underwent clinical tests, is approved by regulatory agencies. Once obtained the approval, a 
pharmaceutical company has the right to sell the drug under the aforementioned patent protection. In this 
terminal phase, named commercialisation phase 
order to detect possible side effects which could manifest themselves only when the drug is widely spread. 
The entire R&D process commonly takes until 15 years to be completed and it costs around US$ 15 million. 
Furthermore, expenditures per approved drug are magnified by the development costs of those drugs 
which failed to be marketed or whose revenues didn’t match their own R&D costs.
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2.1 Risk components 
 
High expenditures and failure rates make the pharmaceutical R&D process extremely risky. These risks are 
usually divided in two components, namely economic and technical. [4] Economic risk deals with factors 
which increase market uncertainty, like interest rates, inflation and changes in industry prices. This kind of 
risk is systematic because a company can’t affect it. In the pharmaceutical industry, economic risk 
manifests itself in the volatility of the drugs future values which may be caused either by a market 
reduction or by the commercialisation of a rival product. On the other hand, technical risk stems from the 
lack of certainty about the process success. Researchers cannot guarantee in advance for safe and effective 
drugs, able to successfully complete all clinical tests and gain the FDA approval as well. As a matter of fact, 
side effects or drug ineffectiveness might manifest themselves in any phase of the process, leading to early 
end of the development process. Technical risk deals with factors related to the projects such as approval 
probability and uncertainty in development costs, and it’s thereby referred to as unsystematic. 
 
3. Pharmaceutical R&D project evaluation 
 
The evaluation of investment projects is generally done by using discounted cash flow based methods such 
as net present value. However, in the field of R&D projects, where high uncertainty and risks are prominent, 
these methods lose a large amount of their effectiveness. In fact, as said before, they fail to correctly assess 
the real value of these projects which results, among other things, from the flexibility possessed by the 
management and from the several opportunities these kinds of investments offer. Using traditional 
methods like NPV to evaluate R&D projects might lead to two different kinds of errors. The first one 
concerns the assumption of static cash flows. This hypothesis ignores the flexibility available to 
management such as the chance to interrupt a project in order to avoid losses, for example in case of 
failures in drug testing (technical risk) or negative market variations (economic risk). The second one, which 
is perhaps the biggest source of inaccurate R&D project evaluation, is the assumption that risk always 
reduces the projects value. Actually, the higher the volatility of the project cash flows is, which is directly 
connected to project riskiness, the higher the likelihood of large future incomes is. This is particularly true 
in pharmaceutical R&D projects, in which the staged process allows the management to move a drug 
development project into the next stage of its process only if the expected results appear to be satisfactory. 
Although traditional methods are still the most frequently used for evaluation of R&D projects, the 
enormous pressure to innovate, especially in the pharmaceutical industry, forces the companies to use 
more sophisticated instruments which are more accurate in evaluation of chances and risks of R&D 
projects, in order to choose the right ones and avoid the risk of missing profitable opportunities. So, in 
recent years, the evaluation of pharmaceutical R&D projects through real options based methods has 
gained growing attention. As a matter of fact, real options methods are able to model the uncertainty and 
the flexibility embedded in the R&D process and to consider the value of future opportunities. 
Real options are options whose underlying asset is a capital investment and not a financial instrument. 
Thus, a real option gives the right, but not the obligation, to undertake a business decision, which generally 
is the chance to make, abandon, expand, or contract a capital investment. The real options analysis (ROA) 
applies the financial options evaluation techniques, like Black & Scholes formula or binomial method, to 
capital budgeting decisions [5]. This real options based method, unlike the traditional ones, allows 
modelling the particular features of pharmaceutical R&D projects as uncertainty and flexibility and that is 
why it suits better than cash flow based methods to evaluate this kind of projects. The basic idea of ROA is 
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to consider the opportunities embedded in a project, or the whole project itself, as real options whose 
value is estimated and subsequently added to the project’s basic NPV. As said before, financial options 
models are used to evaluate a project modelled as a real option and usually require six input variables 
which are underlying value, exercise price, volatility, time to maturity and riskless interest rate. These input 
variables have a real counterparts in actual capital investments, as shown in Table 1, and have to be 
estimated before valuing a real option. 
 
Variable Financial option Real option 
S Underlying asset value Present value of project expected incomes 
X Exercise price Present value of project investment cost 
T Time to maturity 
Length of time in which the investment 
opportunity exists 
σ Volatility of returns on stock Volatility of project cash flows 
r Riskless interest rate Riskless interest rate 
Table 1. Input variables used in financial options and real options evaluation 
 
The first step to take for the evaluation of a capital investment through ROA consists of detecting which 
kind of real option is inherent in the project itself. There are five main different kinds of real options which 
may be embedded in a project, namely: the growth option, the option to abandon an investment project, 
the option to defer an investment project, the option to contract, expand or temporarily shut down an 
investment, the option to switch input or output. Abandon options and growth options are generally used 
to model the pharmaceutical R&D projects. Abandon options are used to model the chance owned by the 
managers to interrupt the development of a drug in any stage of its R&D process, if they consider it no 
longer profitable. The growth options approach, on the other hand, considers a new stage of the R&D 
process as an option which will be exercised if its expected outcomes are satisfying. Growth options are 
also used to model the opportunity of a future new molecule development using the knowledge deriving 
from the current project. 
 
4. Literature review 
 
Real options researches support pharmaceutical R&D process basically through two different approaches: 
the first one aims at evaluating a single R&D project, while the second focuses on the entire R&D portfolio.  
In the following sub-sections, a literature review, which shows the most notable applications of these 
approaches, is provided. 
 
4.1 Single options evaluation 
 
As above mentioned, the first approach identifies the single real options embedded in a project and 
considers them as they were independent of each other. In literature, it  is dealt with fundamentally in two 
ways: the first one is the simplest one since it allows evaluating the options one by one, using standard 
models as the Black & Scholes formula or the binomial method, while the second one models the entire 
project as a compound option. As Bowman and Moskowitz pointed out [6], the first application of ROA in 
the evaluation of a pharmaceutical R&D project was carried out by Merck, one of the most important 
pharmaceutical company, in the early 1990’s. At that time, Merck was evaluating the chance of investing on 
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a new technology which would have allowed it to develop a new drug. Merck considered the whole project 
as a growth option. In fact, if this technology had failed to produce a commercially valuable product, then 
Merck would have been under no obligation to build the plant and incur the start-up costs. Since a growth 
option could be considered as a call option, and its value was therefore assessed by Merck using the Black 
& Scholes formula. The input variables identified by Merck in this process were the ones that will be used 
afterwards in almost all the following pharmaceutical R&D project evaluations. For the underlying asset 
value, Merck took the expected present value of the cash flows deriving from the commercialization of the 
drug. The exercise price was the cost of building the plant and its associated start-up costs. The time to 
expiration was based on the expected time to develop the product while the volatility was based on the 
annual average standard deviation of returns for pharmaceutical industry. With this approach, an 
investment is favourable if the theoretical value of the growth option exceeds the sum of the cost of the 
new technology plus the present value of the R&D costs. A different approach to model a pharmaceutical 
R&D project, as shown by Ollila in the Orion Pharma case [7] and Kellog and Charnes in the Agouron’s 
Viracept case [8], is to consider the chance owned by the management to abandon the project in any stage 
of its development process. Obviously, the real option embedded in the project is the abandon option, 
which is generally considered as an American put option. A closed-form model, such as the Black & Scholes 
formula, cannot be used to calculate the value of this type of option, so it’s necessary to use a numerical 
method like the binomial one. The same input variables of the Merck case may be used also in this abandon 
option approach, with the exception of the exercise price which in this case is the R&D cost that the 
company pays to continue the development process of a drug. Kellog and Charnes provided also an 
empirical proof about the advantage of using ROA instead of traditional methods as NPV. They compared 
the actual Agouron’s market value in certain periods, with its theoretical value calculated both with ROA 
and NPV, proving that the ROA value was closer to the real value of the stocks than the NPV value. As said 
before, there is another way to model and evaluate a pharmaceutical R&D project using ROA, which is 
through the compound options. To evaluate this kind of options, and thus the projects modelled with them, 
it is possible to use either ad hoc methods as Geske model or numerical methods as the binomial model. 
Perlitz et al. [9] displayed how to apply the Geske model to fulfil this purpose, providing a case study 
application. The model requires the R&D process, which is typically divided into 5 phases, to be split into 
two main parts, where the first one concerns the three phases of clinical tests while the second one regards 
the commercialization phase. Each of them can be assimilated to single growth options, with their own 
exercise prices and time to maturity, which altogether form a compound option where the latter serves as 
underlying asset of the first one. Once the input variables of both options have been estimated, the value 
of the compound option can be assessed analytically using the Geske formula, which is based on the Black 
& Scholes formula and has therefore a closed-form expression as well. Although this approach makes easier 
the project value assessment, it has a rather big limitation in its way of modelling the R&D process since it 
can be divided in only two parts, causing a decreased granularity of analysis. Cassimon et al. [10] overcame 
this issue introducing a generalisation of the Geske model which provides a closed-form formula able to 
calculate the value of a n-fold compound option (traditional Geske model can estimate only the value of a 
2-fold compound option). They applied this extended Geske model to the evaluation of a NDA, modelling 
the R&D process as a series of 6 growth options, each of them related to a particular phase of the process. 
Therefore, the resulting compound option was a 6-fold compound option. Finally, Sereno [11] showed also 
how it is possible to evaluate a pharmaceutical R&D project modelled as a compound option, using a 
numerical method such as the binomial method. This method improves the flexibility of the evaluation but, 
at the same time, makes impossible to automate the calculation of the value through software.  
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4.2 Optimal portfolio selection 
 
However, according to several authors it is better to evaluate the entire R&D project portfolio of a company 
instead of its single projects, in order to consider the relations and the interdependences between them. 
These interdependences, ignored if projects are evaluated one by one, usually deal with limited resources 
consumption, risk balancing and company strategies.  
. The second approach, which is slightly more complex but also more realistic, considers the pharmaceutical 
R&D process as a set of subsequent options dependent of each other. This group of options is called 
compound option whose value is estimated through non-standard method as Geske model. A great 
contribution in this field to scientific literature was brought by Roger et al. [12] who developed a stochastic 
optimization model, called OptFolio, able to identify the most valuable projects among the entire R&D 
project portfolio of a company. The aim of this method is to determine the optimal drug developmental 
portfolio that maximizes real options value (ROV) , overall value of the portfolio, given a set of candidate 
drugs in various stages of development, estimates of the probability of clinical success, duration, 
investment required for the remaining stages and forecasts for the future market. This method models the 
R&D process of each project as a series of continuation/abandonment decisions, where the choice whether 
to continue the development of a drug or not is made at the beginning of each phase as a Bermuda option1. 
To estimate the value of a single project/drug, this method uses the binomial model, where the terminal 
nodes of a phase are called value scenarios. Thus, the overall value of the portfolio is given by the sum of 
the single drugs values. OptFolio uses binary variables to model the presence of a drug in the portfolio in a 
particular phase and in a particular value scenario, while the objective function aims at maximizing the 
portfolio overall value. The model selects which drugs have to be included in the portfolio basing on their 
expected current values, their development costs and their technical and commercial success probabilities. 
Since companies usually have limitations to their R&D expenditures, OptFolio has constraints which limit 
the annual R&D efforts preventing them to exceed a given budget value. Other constraints are used to 
enforce the precedence between the different development phases of a drug and to prevent a drug which 
has been abandoned in an earlier stage to be selected. The resulting model formulation has a recursive 
objective function and eight constraints groups. Despite being particularly close to reality, implementation 
and use of OptFolio turn out to be very complex. As a matter of fact, a pharmaceutical company may find it 
hard to set its optimal project portfolio solving a problem with hundreds of constraints and several dozen 
thousands of variables, with only 20 candidate drugs. This is confirmed by the results of a survey conducted 
by Hartmann and Hassan [13] among the most important pharmaceutical firms in 2005 in order to 
investigate the methods used by companies in the evaluation of their R&D projects. The survey clearly 
confirmed the assumed dominance of NPV-based valuation approaches as, on average, only 20% of the 
pharmaceutical companies use ROA to evaluate their projects. Furthermore, the major reason of this 
lacking of use appeared to be the perceived complexity of this method, since about 30% of the sample 
companies answered that real options are considered too complex. A step toward simplifying this issue was 
made by Wang et al. [14], who developed a fuzzy compound option model to estimate the value of each 
R&D project in a pharmaceutical company pipeline. Particularly, they formulated the R&D portfolio 
selection problem as a fuzzy zero-one integer programming model. Limited resources generally deal with 
the amount of a company’s financial assets assigned to its R&D projects. Therefore, they are usually shared 
by them, meaning that only few projects may be carried out but also that part of the financial outcomes 
resulting from the successfully commercialized drugs could be used to fund the development of new drugs. 
According to Kamien et al. [15], the urgency of self-financing R&D for a company has two reasons. First, the 
                                                           
1
 A type of option that can only be exercised on predetermined dates. 
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external financing may be difficult to obtain without substantial related tangible collateral to be claimed by 
the lender if the project fails. An R&D project that fails generally leaves behind few tangible assets of value. 
Second, the firm might be reluctant to reveal detailed information about the project that would make it 
attractive to outside lenders, fearing its disclosure to potential rivals. Furthermore, Brighi et al. [16] 
remarked that the highest risk related to R&D projects leads to more difficulties to find external financial 
funds, implying some forms of financial constraints. However, self-financing may appear as a signaling 
mechanism, correcting such a market imperfection.  
 
5. The proposed model: Optfolio Light 
 
The aforementioned complexity of OptFolio, both in terms of computational load and implementation 
difficulties, doesn’t boost the companies to entrust the optimal selection of their projects to a real option 
based method. Furthermore, financial interdependencies existing among the projects of a product portfolio 
have to be underlined. This could mean both that selecting a drug to be developed may deduct financial 
resources from the development of other drugs as well as it may provide funds to feed the development of 
new products. In fact, if a drug manages to be commercialized and to achieve satisfactory economic results, 
a company might use part of its incomes to finance other R&D projects. This is, as a matter of fact, one of 
the prominent features of blockbuster drugs. These considerations underline the importance for a 
pharmaceutical company to select a balanced R&D portfolio, composed both of profitable drugs ensuring 
high revenues and successful drugs able to provide profits as well as to finance new drugs development. 
That’s why a new mixed-integer linear programming model, based on OptFolio, was developed to provide 
an affordable way to select the optimal R&D product portfolio from a set of candidate drugs in different 
phases of their development process [17] and decide whether to reinvest part of their market incomes to 
fund further R&D activities. The aim of this new model is to reduce the complexity of OptFolio in order to 
favour its use by the pharmaceutical companies, for example obtaining the chance of solving the 
optimization problem using a simple spreadsheet; this is why we called it Opfolio Light (OL). 
 
5.1 Assumptions 
 
To reduce OptFolio complexity and create the new model some alterations are needed. The first one is the 
way the R&D process is modelled, since, instead of being considered as an abandonment option, it is 
considered either as a growth option, or as a series of growth options, depending on how many 
development phases a candidate drug has to pass through (two in the first case, more than two in the 
second case). This modification allows assessing the value of a candidate drug using a closed-form formula 
instead of the binomial method, making easier the calculations. Particularly, the Black & Scholes formula is 
used for candidate drugs which are about to complete their R&D processes and have only two 
development phases left, while the Geske formula is used for candidate drugs in earlier phases of their 
development. Lastly, if a drug has only one phase to pass through, generally the approval phase, neither 
Black and Scholes nor Geske formula are used, since this situation doesn’t represent an option but rather a 
common investment. Thus, the real options value of this type of drug is equal to its expected NPV. 
Moreover, the new model assumes that if the development of a drug is interrupted in any phase, the drug 
will be dismissed from the optimal portfolio. These two assumptions allow the new model to use a simpler 
binary variable, with only one subscript, (yi where i is a generic candidate drug) to model whether a drug is 
selected to be part of the optimal portfolio, instead of the original OptFolio binary variable which has three 
subscripts (yisk where s is a generic stage of drug development and k is a generic value scenario), simplifying 
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its solving process. This is why it is not necessary anymore to account for the possible presence of a drug in 
the optimal portfolio in a certain phase rather than another one, or in a certain value scenario. Additionally, 
a few assumptions are required in order to obtain a balanced portfolio. They include hypothesis on the 
annual cash flows distribution and on the commercial life of marketed drugs and are described in more 
detail in the following section. 
 
5.2 Mathematical Problem Formulation of Optfolio Light 
 
Sets, parameters and variables 
The starting point of the portfolio planning is the group of candidate drugs P which may be selected to be 
part of the optimal portfolio. At the beginning of the optimal portfolio selection, they can be in any stage of 
their development process. As in the OptFolio, the sets of OL are: 
i = product (i = 1, 2, ..., P) 
s = stage of drug development (s = 1, 2, ..., S) 
t = year of the portfolio planning horizon (t = 0, 1, ..., T) 
And, as OptFolio, for each candidate drug i, portfolio selection decision made at the present time (t = 0) 
classify the impending stage as s = 1 regardless of where the candidate drug is in its development. 
Subsequent development stages are numbered in ascending order until termination at product launch. 
The parameters of OL are: 
V0i = current value of drug i at t = 0 
σi = estimated annual market volatility for drug i 
r = risk-free interest rate 
Tis = length in years of stage s of drug development for drug i 
Iis = investment cost of developmental stage s for drug i 
Φis = probability of technical success in stage s of development for drug i 
Bt = budgetary constraint for year t 
Ci = Real options value of drug i 
Fi = annual cash flow of drug i 
rph = rate of return in the pharmaceutical industry 
n = drugs commercial life 
Xi
R&D = percentage of cash flows of drug i invested in R&D 
Fi
’ = amount of annual cash flow of drug i invested in R&D 
The parameter V0i represents the expected NPV at t = 0 of drug i, namely the sum of the discounted value 
of all cash flows that result from the drug commercialization. The market volatility σi is the standard 
deviation of V0i, which is usually estimated using historical sales data of similar products. The risk-free 
interest rate r corresponds generally to an observable market rate, such as US Treasury Bills. Every 
development stage s of each candidate drug could have different length Tis, investment cost to be carried 
out Iis and probability of technical success Φis. The budgetary constraint Bt is the total amount of financial 
resources that a company can spend for its R&D projects in the year t. 
The real options value Ci is the value of drug i which takes account of the abandonment option embedded 
in the project itself and, as said before, may be calculated by two different expressions. Black & Scholes 
formula must be used if a drug has only two development phase left and presents this expression: 
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and N is the cumulative normal distribution function. 
 
On the other hand, Geske formula must be used when a drug has to pass through more than two phases 
before being commercialised. If the development phases left are only 3, traditional Geske formula can be 
used: 
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Where N1 is the cumulative normal distribution function, while N2 is the bivariate cumulative normal 
distribution function with a1 and a2 as upper limits and ρ as the correlation coefficient between the two 
variables. 
With drugs which have more than three development stages left, the aforementioned extended Geske 
model, developed by Cassimon et al., is needed. However, in order to simplify the analysis, for example in a 
spreadsheet where a n-variate cumulative normal distribution is hard to implement, the traditional 
expression could be used. To do this, s = 2 and s = 3 stages, for instance, could be merged, as the decision 
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to undertake both of them is made at the beginning of the s = 2 stage. This allows the drug to appear as it 
has only 3 stages left instead of 4. The investment/exercise price of this new single stage can be calculated 
as: 
 , =  +  !  (10) 
 
The same might be done for s = 3 and s = 4 or for more stages. 
As mentioned before, further assumptions are needed to achieve a balanced R&D portfolio. The first one of 
them, which concerns the annual revenues distribution of a marketed product, assumes that, after its 
commercialization, a drug provides a company with uniform cash flows Fi for n years. The value of these 
annual incomes for drug i is: 
 
0 =  11 + )2345)2311 + )2345 − 1 
 
(11) 
In this paper, the rate of return in the pharmaceutical industry rph has been assumed equal to 12%, as 
suggested by DiMasi et al. [18]. On the other hand, the life of a drug after its commercialization n has been 
considered equal to 10 years, since after this lapse of time a drug normally loses its patent protection, 
causing its annual incomes to fall dramatically. However, only a share Xi
R&D of annual cash flows is 
potentially reinvested to fund the development of further drugs. Thus, the actual amount of financial 
resources F’
’, deriving from the commercialization of drug  i and planned to be yearly invested in R&D, is: 
 07 = 89&;< 
 
(12) 
where 
 
< = 11 + )2345)2311 + )2345 − 1 
 
(13) 
In the new model there are two binary variables as well as a continuous one for each drug. The first 
variable yi models its presence in the optimal portfolio and it is defined as: 
 
= = >1     ?@ 	)AB ? ?C CD,	 @E) ,ℎ EG,?H GE),@E?E0                                     E,ℎ)I?C                                         J 
 
Using only one variable of this kind per drug allows a massive reduction in the overall variables number and 
has a great positive impact on computational load. 
The second binary variable zi models the decision whether to reinvest part of the cash flows of drug i or 
not, and it is defined as: 
 
K = >1     ?@ G), E@ ,ℎ DCℎ @EIC E@ 	)AB ? ?C )?LC,	0                                          E,ℎ)I?C                                         J 
 
Finally, the continuous variable XR&Di represents the optimal cash flows share of drug i reinvested to fund 
the development of further drugs. 
12 
 
 
  Constraints and objective function 
OL does not need many OptFolio constraints because of its use of closed-form model instead of the 
binomial model. Thus, the only essential constraints group is the one related to budget limitations which is 
expressed as: 
 
M NO,N
=IN",N − M P"89&;Q<K ≤ S"                ∀, 
 
(14) 
The first part of this constraints group refers to the overall R&D expenditures. The binary parameter wist 
appears in the OptFolio model as well and allows to include in budgetary constraints only those drugs 
beginning a stage of development in the period t. The technical success rate Φi,s-1 is included in order to 
consider the expected cost of each selected drug for the period t, and not the actual one. The second part, 
on the other hand, includes the financial contributions brought to R&D by those commercialized drugs 
whose revenues have been partially allocated for this specific purpose. The binary parameter ωit allows the 
contribution of drug i in the period t to be considered only if the drug has been already introduced to the 
market in that period. 
Of course, a drug cannot fund further R&D activities if it has not been selected for the optimal portfolio. 
Thus, the following group of constraints is required: 
 K ≤ =          ∀?  
Finally a constraint on  89&; that expresses a percentage variable:  0 ≤ 89&; ≤ 1 
 
(15) 
 
 
 
(16) 
Complexity reduction is evident also in terms of constraints number which is considerably lower than the 
original OptFolio. It is also possible to insert further constraints groups regarding the consumption of 
limited resources (i.e. human resources) with little increase in computational load. 
As in OptFolio, the objective function deals with maximization of the overall ROV of the product portfolio at 
t = 0, but it is calculated in a different way: 
 
HU VW = M  − 
= − M P"89&;Q<K11 + )234","  
 
(17) 
As well as the budgetary constraint, the objective function is divided in two parts, where the former deals 
with the selection of the candidate drugs to insert in the optimal portfolio while the latter concerns the 
decision to use part of the incomes of a selected drug to fund further R&D activities. Drug i could be 
selected to be part of the optimal portfolio if its real options value exceeds the investment required to start 
its current development stage. Furthermore, part of the incomes of drug i may be reinvested in order to 
allow other drugs to enter the optimal portfolio. In this case, the discounted cash flows used for this 
purpose must be subtracted. Unlike OptFolio objective function, this one is fairly easy to be implemented 
and solved in a spreadsheet, which is the aim of OL. 
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Model formulation 
 
The complete OL formulation is: 
 
max VW = M  − 
= − M P"89&;Q<K11 + )234","  
 subject to 
 
M NO,N
=IN",N − M P"89&;Q<K ≤ S"                ∀, 
 K ≤ =          ∀? 
 0 ≤ 89&; ≤ 1 
 = ∈ d0,1e 
 
Therefore, the model provides a set of drugs constituting the optimal portfolio and a subset of them whose 
future incomes will be partially used to fund the development of other candidate drugs. The resulting 
portfolio is balanced as it contains both profitable products as well as supporting drugs which help the 
pipeline of a company to partially finance itself. The model gives back also the optimal market revenues 
share of this kind of drugs to reinvest. 
 
 5.3 Spreadsheet implementation 
 
The simplicity of OL allowed its implementation in a Microsoft Excel spreadsheet. Any company interested 
in evaluating and selecting its pharmaceutical R&D projects could create its own optimal products portfolio 
simply entering drugs information and clicking a button. Particularly, the model needs inputs regarding 
budget limitations as well as about candidate drugs, such as their expected current values, volatilities, 
technical success rates and investment costs of each stage, and types, which indicates what is the 
impending development stage of a drug at the time of portfolio selection. Thus, the spreadsheet identifies 
whether Black & Scholes formula, Geske formula or none of them is needed for a certain drug and 
calculates the options parameters (as exercise prices, d1 and d2 for Black & Scholes formula, a1, a2, b1 and b2 
for Geske formula) useful for estimating its real options value Ci. At last, it is sufficient to click on a macro 
button which launches the Excel solver, finding the balanced optimal portfolio composition. Fig.3 
summarizes the described steps. 
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Fig. 3. Optimal portfolio selection process using the new model spreadsheet 
 
6. Case study 
 
In order to show how the model works and demonstrate its simplicity and effectiveness, a case study 
concerning a balanced optimal portfolio selection is provided. The starting product portfolio chosen to test 
the model comes from the paper by Rogers et al. [12] where OptFolio has been introduced, and contains 20 
candidate drugs in different stages of their development process. Given the finite level of resources 
available, it is not possible to take all of them into clinical development simultaneously, so, different 
distributions of budget constraints have been tested. The drugs characteristics are summarised in table 2. 
 
Candidate 
drugs 
Type Beginning phase 
1 1 Phase I 
2 1 Phase I 
3 1 Phase I 
4 1 Phase I 
5 1 Phase I 
6 1 Phase I 
7 2 Phase II 
8 2 Phase II 
9 2 Phase II 
10 2 Phase II 
11 2 Phase II 
12 3 Phase III 
13 3 Phase III 
14 3 Phase III 
15 4 2nd year Phase III 
16 4 2nd year Phase III 
17 5 FDA Approval 
18 5 FDA Approval 
19 5 FDA Approval 
20 5 FDA Approval 
Table 2. Description of the candidate drugs 
 
INPUTS
•Drugs parameters
•V0
•σ
•Φ
•I
•type
•Pharmaceutical industry 
parameters
•Budget limitations
•Risk-free interest rate
OPTIONS PARAMETERS
•Model
•Exercise price(s)
•a1, a2, b1, b2, ...
•Ci
OUTPUT
•Optimal portfolio 
composition
•Supporting drugs
•Optimal reinvestment 
share
•Max ROV
 The length of phase I and II have been assumed equal to 1 year, while the length of phase III and ap
equal to 2 years, with an overall 6 years length R&D process
considered as M$ 400 for the first year and M$ 100 for the remaining ones
years. Finally, the risk-free interest rate h
years US treasury bond2. The screenshot of the model implemented in Excel, shown in fig. 4, summarizes 
the overall candidate drugs inputs.  
Fig 4. Screenshot showing the candidate drugs inputs
The screenshots depicted in figures 5 and 6 show the automatically assessed options parameters. The 
model recognizes which method is needed to evaluate a drug and calculates the parameters useful for this 
purpose as well as the final drug value.
 
                                                          
2
 Source: www.bloomberg.com (January 2011)
. Budget limitation
, with a planning horizon of 5 
as been set at 3.41% which corresponds to a December 2010 5
 
 
 
 
 
15 
proval 
 have been initially 
-
 
 Fig. 5. Screenshot showing options parameters and evaluation method required
Fig. 6. Screenshot showing the parameters of the drugs evaluation methods and the drugs values
Finally, the last screenshot in figure 7 shows the 
100 M$ for the others. Particularly, the selected drugs have been P2, P5, P7, P15 and P20, with an overall 
ROV of M$ 1,494.28, while 83,34
subsequent R&D activities. It is indeed worth noting that if this problem had been solved with the same 
budget constraints but without any self
to M$ 1,401.34. In fact, just the reinvested market revenues of drug P
development of the profitable drug P5, leading to higher portfolio ROV.
 
 
 
 
 
solution for a budget of 400 M$ 
% of the future incomes of drug P15 will be used to partially fund 
-financing chances, it would have led to a lower overall ROV, equal 
15 would allow, for example, the 
 
 
16 
 
 
 
for the first year and of 
 Fig. 7. Screenshot showing the optimal portfolio composition and the overall ROV
In order to study the effect of the investment constraint on the 
yearly budget limitations have been tested. 
budget and the following ones have been tried out. They are shown in Table 
optimal portfolio composition and overall ROV, the supporting drugs and their correspondent percentage 
of reinvested cash flows. 
 
1st year 
budget 
Next 
years 
budget 
400 100 
400 200 P2, P5, P10, P14, P15, P16, P19
400 300 P2, P4, P5, P10, P14, P15, P16, P19
500 100 
500 200  P5, P10, P14, P15, P16, P20
500 300 P2, P4, P5, 
600 100 
600 200 P5, P10, P14, P15, P16, P20
600 300 P2, P4, P5, P7, P8, P9, P10, P11, P12, P14, P15, P16, P20
Table 3. Optimal po
The same results are displayed in the following graphs, which shows the trend of the optimal ROV as the 
budget limitations change. 
 
 
optimal portfolio composition, different 
Particularly, different combinations between the first year 
3, together with the resulting 
Porftolio composition ROV 
P2, P5, P7, P15, P20 $1,494.28 
 $1,868.40 
 $1,948.61 
P5, P7, P14, P15 P20 $1,646.40 
 $2,118.40 
P10, P14, P15, P16, P20 $2,198.61 
P5, P7, P15, P18, P20 $1,812.72 
 $2,118.40 
 $2,341.65 
rtfolio composition for different budget limitations
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Supporting 
drugs 
R&D 
share 
P15 83.34% 
- - 
P15 18.36% 
P20 46.68% 
- 8.35% 
P15 11.02% 
P15 45.20% 
- - 
P16 18.36% 
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Fig. 8. Graph of optimal ROV for different budget limitations 
 
It is possible to observe that almost every budget combination has a supporting drug which gives a certain 
amount of its future revenues allowing more drugs to be part of the optimal portfolio. Furthermore, a 
comparison between the optimal portfolio ROV in case of presence and absence of self-financing, for 
different budget combinations, is shown in Table 4 (in brackets the corresponding optimal portfolio 
composition). 
 
 
 Self financing (SF) 
1
st
 year budget 
 
 
400.00 500.00 600.00 
N
e
x
t 
y
e
a
rs
 b
u
d
g
e
t 
100.00 
SF 
1,494.28 
(P2, P5, P7, P15, 
P20) 
1,646.40 
(P5, P7, P14, 
P15 P20) 
1,812.72 
(P5, P7, P15, 
P18, P20) 
no SF 
1,389.15 
(P3, P10, P15, 
P20) 
1,418.27 
(P3, P10, P12, 
P15, P20) 
1,694.46 
(P15, P19, P20) 
200.00 
SF 
1,868.40 
(P2, P5, P10, 
P14, P15, P16, 
P19) 
2,118.40 
(P5, P10, P14, 
P15, P16, P20) 
2,118.40 
(P5, P10, P14, 
P15, P16, P20) 
no SF 
1,868.40 
(P2, P5, P10, 
P14, P15, P16, 
P19) 
2,118.40 
(P5, P10, P14, 
P15, P16, P20) 
2,118.40 
(P5, P10, P14, 
P15, P16, P20) 
300.00 
SF 
1,948.61 
(P2, P4, P5, P10, 
P14, P15, P16, 
P19) 
2,198.61 
(P2, P4, P5, P10, 
P14, P15, P16, 
P20) 
2,341.65 
(P2, P4, P5, P7, 
P8, P9, P10, 
P11, P12, P14, 
P15, P16, P20) 
no SF 
1,923.66 
(P3, P5, P10, 
P14, P15, P16, 
P19) 
2,173.66 
(P3, P5, P10, 
P14, P15, 16, 
P20) 
2,329.16 
(P4, P5, P7, P8, 
P9, P10, P11, 
P12, P14, P15, 
P16, P20) 
     
Table 4. Comparison between the optimal portfolio ROVs [M$] 
 
0
500
1.000
1.500
2.000
2.500
100 200 300
400
500
600
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It is evident that having the chance to reinvest part of drugs profits provides pharmaceutical companies 
with higher overall ROV. 
7. Conclusion 
 
This paper focused on application of real options methods to evaluate pharmaceutical R&D projects, 
presenting the state of the art regarding models and techniques which suit this particular aim. These 
methods were compared with traditional evaluation methods like NPV, which fail to properly assess the 
value of this kind of projects, since they don’t take account of the opportunities usually embedded in R&D 
projects. Moreover, as the value of these chances is very high in risky and long term projects, such as those 
carried out by pharmaceutical companies, the use of real options based methods allows to improve the 
accuracy in their evaluation. Particularly, this article dealt with selection of an optimal R&D project 
portfolio, through real options, which is also able to establish whether is favourable for a company to use 
part of the future financial incomes of its commercialized drugs to fund the development of other products, 
in order to achieve balance in its strategic planning. This is done by presenting a model available in 
literature and providing a new one which aims to overcome the drawbacks of the already existing one that 
limited its spread across the companies and to provide balance in terms of self-financing. To do this, some 
modifications were made to the original model, in order to built up a new one which is more 
comprehensible and fairly easy to implement in a simple spreadsheet. The resulting portfolio is balanced 
since it contains both drugs whose aim is to provide pharmaceutical companies with large revenues and 
drugs which are able to fund further R&D activities sharing part of their financial incomes. This may lead 
pharmaceutical companies to higher profits and increasing growth rates. A case study, based on the 
selection of an optimal drugs portfolio among twenty products, is provided to prove the simplicity and 
effectiveness of the new model. Since only data entry and a click of a button are required to launch this 
model, it might be helpful to many pharmaceutical companies as a support for their strategic decisions. As 
a further study, it may be worth to slightly modify the new model in order to extend its field of application. 
The possible extension is twofold: it can be fitted, with minor revisions, to other industries and within 
biopharmaceutical industry the model would be useful to evaluate open innovation opportunities.  
Particularly, it could be possible to use it to evaluate licensing deals and alliances between pharmaceutical 
and biotechnology companies, as already done by Rogers et al. with the OptFolio model [18]. Using the 
same approach focused on simplification, a decision support system might be created in order to help 
pharmaceutical companies to develop their strategic plans. 
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